Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael J. Hitchcock
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Beta
- -0.30
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -17.70
Financials
Net Income
$-8.33MEBITDA
$-8.33MFree Cash Flow
$-10.03MEPS (diluted)
$-0.12Shares Outstanding (diluted)
72.36M+575.8%Operating Expenses
$12.77MCash & Debt
$34.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-61.80M | $-1.18 |
| 2024 | $0.00 | $-138.43M | $-3.83 |
| 2023 | $0.00 | $-117.25M | $-3.44 |
| 2022 | $0.00 | $-81.83M | $-2.80 |
| 2021 | $0.00 | $-41.57M | $-1.74 |
| 2020 | $0.00 | $-5.32M | $-0.50 |
| 2019 | $0.00 | $-1.20M | $-0.11 |
Valuation
BMEAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsinvezz.com·6h ago·Neutral
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $-0.21 per share
Typical surprise +13.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.12 vs $-0.22beat
- Mon, May 11$-0.17 vs $-0.24beat
- Tue, Mar 24$-0.64 vs $-0.25miss
- Tue, Nov 4$-0.27 vs $-0.26miss
- Tue, Aug 5$-0.51 vs $-0.59beat
- Mon, May 5$-0.80 vs $-0.84beat
Estimates and results for BMEA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BMEA officers and directors.
- Bought
- $13.8m
- Sold
- $32.8m
15 trades
10 trades
- Erdtmann Rainer Mbought
- Hitchcock Michael J.m.bought
- Erdtmann Rainer Mbought
- Erdtmann Rainer Mbought
- Hitchcock Michael J.m.bought
- Valle Francobought
- A2a Pharmaceuticals, Inc.sold
- A2a Pharmaceuticals, Inc.sold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.